創薬サービス市場：世界の市場規模、シェア、動向分析、機会、予測レポート、2019年-2029年

創薬サービスの世界市場が2.8倍に急拡大、2029年には530億米ドルに達する

世界の創薬サービス市場は、製薬会社やバイオテクノロジー企業による研究開発投資の増加、創薬の複雑化、慢性疾患の増加、医薬品開発・承認プロセスの合理化・迅速化を目指す政府の取り組みなどにより活況を呈しています。

戦略コンサルティング・市場調査の大手であるBlueWeave Consultingは、最近の調査で、2022年の世界の創薬サービス市場規模を185億米ドルと推定しました。2023年から2029年の予測期間中、BlueWeaveは世界の創薬サービス市場規模がCAGR 15.2%で成長し、2029年には528億米ドルに達すると予測しています。疾病の複雑化と個別化医療の必要性により、新薬の発見はより困難になっています。この複雑さには、学際的なアプローチと専門的な専門知識が必要であり、それはアウトソーシングによって得ることができます。製薬会社やバイオテクノロジー企業は、新薬や治療法を発見するための研究開発活動に多額の投資を行っています。創薬プロセスの特定の段階をアウトソーシングすることで、専門的な知識やリソースをより効率的に利用することができます。さらに、製薬会社、学術機関、CRO間の共同パートナーシップは、創薬においてますます一般的になってきています。このようなパートナーシップにより、知識の共有、専門知識へのアクセス、リソースの共有が促進され、イノベーションが促進され、市場の成長が促進されます。

本レポートの詳細な分析により、成長の可能性、今後の動向、世界の創薬サービス市場の統計に関する情報を提供します。また、総市場規模の予測を促進する要因にも焦点を当てています。当レポートは、世界の創薬サービス市場における最近の技術動向を、業界考察とともに提供し、意思決定者が健全な戦略的意思決定を行えるよう支援します。さらに、市場の成長促進要因・課題・競争力についても分析しています。

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界の創薬サービス市場に関する洞察

• 業界のバリューチェーン分析
• DROC分析
  • 成長の原動力
    • 慢性疾患の蔓延
    • 創薬活動のアウトソーシング
    • 研究開発費の増加
  • 抑制要因
    • 厳しい規制要件
    • 高い失敗率
  • 機会
    • 個別化医療の出現
    • 希少疾病と希少疾病用医薬品への注目の高まり
  • 課題
    • 倫理的懸念と世間の認識
• 技術の進歩/最近の開発
• 規制の枠組み
• ポーターのファイブフォース分析
• 世界の創薬サービス市場概要
• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • タイプ別
    • 化学サービス
    • 生物学サービス
  • プロセス別
    • ターゲットの検証
    • ターゲットの選定
    • H2Lの識別
    • 候補の検証
    • リードの最適化
  • 薬剤タイプ別
    • 生物学的製剤
    • 低分子薬
  • 治療領域別
    • 神経科
    • 感染症・免疫系疾患
    • 消化器系疾患
    • 腫瘍
    • その他
  • エンドユーザー別
    • 製薬・バイオテクノロジー企業
    • 学術機関
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋（APAC）
    • ラテンアメリカ（LATAM）
    • 中東・アフリカ（MEA）

第4章 北米の創薬サービス市場

• 市場規模と予測、2019～2029年
• 金額別
• 市場シェアと予測
  • タイプ別
  • プロセス別
  • 薬剤タイプ別
  • 治療領域別
  • エンドユーザー別
  • 国別
    • 米国
    • タイプ別
    • プロセス別
    • 薬剤タイプ別
    • 治療領域別
    • エンドユーザー別
    • カナダ
    • タイプ別
    • プロセス別
    • 薬剤タイプ別
    • 治療領域別
    • エンドユーザー別

第5章 欧州の創薬サービス市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • タイプ別
  • プロセス別
  • 薬剤タイプ別
  • 治療領域別
  • エンドユーザー別
  • 国別
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • ベルギー
    • ロシア
    • オランダ
    • その他欧州

第6章 アジア太平洋の創薬サービス市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • タイプ別
  • プロセス別
  • 薬剤タイプ別
  • 治療領域別
  • エンドユーザー別
  • 国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリアとニュージーランド
    • インドネシア
    • マレーシア
    • シンガポール
    • ベトナム
    • APACのその他諸国

第7章 ラテンアメリカの創薬サービス市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • タイプ別
  • プロセス別
  • 薬剤タイプ別
  • 治療領域別
  • エンドユーザー別
  • 国別
    • ブラジル
    • メキシコ
    • アルゼンチン
    • ペルー
    • その他ラテンアメリカ

第8章 中東・アフリカの創薬サービス市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • タイプ別
  • プロセス別
  • 薬剤タイプ別
  • 治療領域別
  • エンドユーザー別
  • 国別
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • クウェート
    • 南アフリカ
    • ナイジェリア
    • アルジェリア
    • MEAの残りの部分

第9章 競合情勢

• 主要企業とその製品のリスト
• 世界の創薬サービス企業の市場シェア分析、2022年
• 動作パラメータによる競合ベンチマーキング
• 主要な戦略的展開（合併、買収、パートナーシップ）

第10章 世界の創薬サービス市場に対するCOVID-19の影響

第11章 企業プロファイル（会社概要、財務マトリックス、競合情勢、主要な人材、主要な競合、連絡先住所、戦略的展望、 SWOT分析）

• General Electric
• Eurofins Scientific
• Syngene International Limited
• Wuxi AppTec
• Frontage Labs
• Domainex
• WIL Research Laboratories LLC
• Shanghai Medicilon, Inc.
• Labcorp Drug Development
• Jubilant Biosys Ltd.
• Evotec
• Shanghai ChemPartner
• Charles River Laboratories
• Merck & Co. Inc.
• Thermo Fisher Scientific Inc.
• Other Prominent Players

第12章 主要な戦略的推奨事項

第13章 調査手法

Global Drug Discovery Services Market Zooming 2.8X to Reach USD 53 Billion by 2029

Global drug discovery services market is booming due to the increasing R&D investments by pharmaceutical companies and biotechnology firms, complexity of drug discovery, increasing prevalence of chronic diseases, and government initiatives to streamline and expedite the drug development and approval process.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global drug discovery services market size at USD 18.5 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global drug discovery services market size to grow at a CAGR of 15.2% reaching a value of USD 52.8 billion by 2029. The discovery of new drugs has become more challenging due to the complexity of diseases and the need for personalized medicine. This complexity requires a multidisciplinary approach and specialized expertise, which can be obtained through outsourcing. Pharmaceutical companies and biotechnology firms are investing heavily in research and development activities to discover new drugs and therapies. Outsourcing certain stages of the drug discovery process allows them to access specialized expertise and resources more efficiently. Furthermore, collaborative partnerships between pharmaceutical companies, academic institutions, and CROs have become increasingly common in drug discovery. These partnerships facilitate knowledge sharing, access to specialized expertise, and resource pooling, fostering innovation and driving market growth.

Opportunity: Increasing Focus on Drug Research and Development

The pursuit of innovative and effective therapeutics is driving the pharmaceutical industry to allocate larger budgets towards R&D. As the global burden of diseases continues to rise, there is a growing demand for novel drugs that can address unmet medical needs. Pharmaceutical companies are motivated to invest more in R&D to discover breakthrough treatments, resulting in increased demand for drug discovery services. The advances in scientific knowledge and technologies have expanded the scope and complexity of drug discovery research. With the advent of genomics, proteomics, high-throughput screening, computational modelling, and other cutting-edge tools, the process of identifying and developing new drug candidates has become more intricate. These advancements require substantial investments in specialized equipment, expertise, and infrastructure, which in turn drive up R&D expenditures.

Impact of COVID-19 on the Drug Discovery Services Market

The COVID-19 pandemic had a profound impact on the drug discovery services market, affecting various aspects of the industry. The pandemic led to a heightened focus on infectious diseases. The urgent need for treatments and vaccines for COVID-19 drove significant investments and collaborations in research and development related to infectious diseases. Many drug discovery service providers redirected their efforts towards developing drugs and therapies specifically targeting the virus. This shift resulted in an increased demand for services related to target identification, lead optimization, and preclinical testing for infectious diseases. The limitations imposed by the pandemic accelerated the adoption of virtual screening and computational approaches in drug discovery. With physical laboratory work being restricted, drug discovery service providers increasingly relied on computer simulations, artificial intelligence, and machine learning algorithms to identify potential drug candidates. These technologies have played a crucial role in continuing research activities despite the limitations imposed by the pandemic. They enabled virtual collaborations, data analysis, and the identification of drug targets.

Global Drug Discovery Services Market - By Type:

Based on type, the global drug discovery services market is bifurcated into chemistry services and biology services segments. During the period in analysis, the chemistry services segment is expected to hold a significant market share due to the broad use of chemical services at various early stages of drug development to produce reliable drug candidates. The widespread use of chemistry in academia, biotechnology firms, and sizable pharmaceutical businesses also contributes to industry expansion.

Global Drug Discovery Services Market - By Process:

Based on process, the global drug discovery services market is segmented into target validation, target selection, hit-to-lead identification, candidate validation, and lead optimization. During the forecast period, Hit-To-Lead Identification is expected to hold a significant market share. Hit-To-Lead Identification is an early stage in the drug discovery process, where potential drug candidates, known as hits, are identified and further optimized into leads. As drug discovery efforts increase, there is a growing demand for services that focus on this crucial stage. The combination of specialized expertise, advanced screening technologies, computational approaches, and the ability to optimize hits into leads positions the Hit-To-Lead Identification segment as a significant player in the global drug discovery services market.

Competitive Landscape:

The drug discovery services market is fragmented, with numerous players serving the market. The key players dominating the global drug discovery services market include General Electric, Eurofins Scientific, Syngene International Limited, Wuxi AppTec, Frontage Labs, Domainex, WIL Research Laboratories LLC, Shanghai Medicilon, Inc., Labcorp Drug Development, Jubilant Biosys Ltd, Evotec, Shanghai ChemPartner, Charles River Laboratories, Merck & Co. Inc., Thermo Fisher Scientific Inc. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisition to expand their customer reach and gain a competitive edge in the overall market.

The report's in-depth analysis provides information about growth potential, upcoming trends, and the Global Drug Discovery Services Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Drug Discovery Services Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Drug Discovery Services Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Growing prevalence of chronic diseases
    • 3.2.1.2. Outsourcing of drug discovery activities
    • 3.2.1.3. Increasing R&D expenditure
  • 3.2.2. Restraints
    • 3.2.2.1. Stringent regulatory requirements
    • 3.2.2.2. High failure rates
  • 3.2.3. Opportunities
    • 3.2.3.1. Emergence of personalized medicine
    • 3.2.3.2. Increasing focus on rare diseases and orphan drugs
  • 3.2.4. Challenges
    • 3.2.4.1. Ethical concerns and public perception
• 3.3. Technology Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry
• 3.6. Global Drug Discovery Services Market Overview
• 3.7. Market Size & Forecast, 2019-2029
  • 3.7.1. By Value (USD Billion)
• 3.8. Market Share & Forecast
  • 3.8.1. By Type
    • 3.8.1.1. Chemistry Services
    • 3.8.1.2. Biology Services
  • 3.8.2. By Process
    • 3.8.2.1. Target Validation
    • 3.8.2.2. Target Selection
    • 3.8.2.3. Hit-To-Lead Identification
    • 3.8.2.4. Candidate Validation
    • 3.8.2.5. Lead Optimization
  • 3.8.3. By Drug Type
    • 3.8.3.1. Biologics
    • 3.8.3.2. Small Molecule Drugs
  • 3.8.4. By Therapeutic Area
    • 3.8.4.1. Neurology
    • 3.8.4.2. Infectious & Immune System Diseases
    • 3.8.4.3. Digestive System Diseases
    • 3.8.4.4. Oncology
    • 3.8.4.5. Others
  • 3.8.5. By End User
    • 3.8.5.1. Pharmaceutical & Biotechnology Companies
    • 3.8.5.2. Academic Institutes
    • 3.8.5.3. Others
  • 3.8.6. By Region
    • 3.8.6.1. North America
    • 3.8.6.2. Europe
    • 3.8.6.3. Asia Pacific (APAC)
    • 3.8.6.4. Latin America (LATAM)
    • 3.8.6.5. Middle East and Africa (MEA)

4. North America Drug Discovery Services Market

• 4.1.1. Market Size & Forecast, 2019-2029
• 4.1.2. By Value (USD Billion)
• 4.2. Market Share & Forecast
  • 4.2.1. By Type
  • 4.2.2. By Process
  • 4.2.3. By Drug Type
  • 4.2.4. By Therapeutic Area
  • 4.2.5. By End User
  • 4.2.6. By Country
    • 4.2.6.1. United States
    • 4.2.6.1.1. By Type
    • 4.2.6.1.2. By Process
    • 4.2.6.1.3. By Drug Type
    • 4.2.6.1.4. By Therapeutic Area
    • 4.2.6.1.5. By End User
    • 4.2.6.2. Canada
    • 4.2.6.2.1. By Type
    • 4.2.6.2.2. By Process
    • 4.2.6.2.3. By Drug Type
    • 4.2.6.2.4. By Therapeutic Area
    • 4.2.6.2.5. By End User

5. Europe Drug Discovery Services Market

• 5.1. Market Size & Forecast, 2019-2029
  • 5.1.1. By Value (USD Billion)
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Process
  • 5.2.3. By Drug Type
  • 5.2.4. By Therapeutic Area
  • 5.2.5. By End User
  • 5.2.6. By Country
    • 5.2.6.1. Germany
    • 5.2.6.1.1. By Type
    • 5.2.6.1.2. By Process
    • 5.2.6.1.3. By Drug Type
    • 5.2.6.1.4. By Therapeutic Area
    • 5.2.6.1.5. By End User
    • 5.2.6.2. United Kingdom
    • 5.2.6.2.1. By Type
    • 5.2.6.2.2. By Process
    • 5.2.6.2.3. By Drug Type
    • 5.2.6.2.4. By Therapeutic Area
    • 5.2.6.2.5. By End User
    • 5.2.6.3. Italy
    • 5.2.6.3.1. By Type
    • 5.2.6.3.2. By Process
    • 5.2.6.3.3. By Drug Type
    • 5.2.6.3.4. By Therapeutic Area
    • 5.2.6.3.5. By End User
    • 5.2.6.4. France
    • 5.2.6.4.1. By Type
    • 5.2.6.4.2. By Process
    • 5.2.6.4.3. By Drug Type
    • 5.2.6.4.4. By Therapeutic Area
    • 5.2.6.4.5. By End User
    • 5.2.6.5. Spain
    • 5.2.6.5.1. By Type
    • 5.2.6.5.2. By Process
    • 5.2.6.5.3. By Drug Type
    • 5.2.6.5.4. By Therapeutic Area
    • 5.2.6.5.5. By End User
    • 5.2.6.6. Belgium
    • 5.2.6.6.1. By Type
    • 5.2.6.6.2. By Process
    • 5.2.6.6.3. By Drug Type
    • 5.2.6.6.4. By Therapeutic Area
    • 5.2.6.6.5. By End User
    • 5.2.6.7. Russia
    • 5.2.6.7.1. By Type
    • 5.2.6.7.2. By Process
    • 5.2.6.7.3. By Drug Type
    • 5.2.6.7.4. By Therapeutic Area
    • 5.2.6.7.5. By End User
    • 5.2.6.8. The Netherlands
    • 5.2.6.8.1. By Type
    • 5.2.6.8.2. By Process
    • 5.2.6.8.3. By Drug Type
    • 5.2.6.8.4. By Therapeutic Area
    • 5.2.6.8.5. By End User
    • 5.2.6.9. Rest of Europe
    • 5.2.6.9.1. By Type
    • 5.2.6.9.2. By Process
    • 5.2.6.9.3. By Drug Type
    • 5.2.6.9.4. By Therapeutic Area
    • 5.2.6.9.5. By End User

6. Asia-Pacific Drug Discovery Services Market

• 6.1. Market Size & Forecast, 2019-2029
  • 6.1.1. By Value (USD Billion)
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Process
  • 6.2.3. By Drug Type
  • 6.2.4. By Therapeutic Area
  • 6.2.5. By End User
  • 6.2.6. By Country
    • 6.2.6.1. China
    • 6.2.6.1.1. By Type
    • 6.2.6.1.2. By Process
    • 6.2.6.1.3. By Drug Type
    • 6.2.6.1.4. By Therapeutic Area
    • 6.2.6.1.5. By End User
    • 6.2.6.2. India
    • 6.2.6.2.1. By Type
    • 6.2.6.2.2. By Process
    • 6.2.6.2.3. By Drug Type
    • 6.2.6.2.4. By Therapeutic Area
    • 6.2.6.2.5. By End User
    • 6.2.6.3. Japan
    • 6.2.6.3.1. By Type
    • 6.2.6.3.2. By Process
    • 6.2.6.3.3. By Drug Type
    • 6.2.6.3.4. By Therapeutic Area
    • 6.2.6.3.5. By End User
    • 6.2.6.4. South Korea
    • 6.2.6.4.1. By Type
    • 6.2.6.4.2. By Process
    • 6.2.6.4.3. By Drug Type
    • 6.2.6.4.4. By Therapeutic Area
    • 6.2.6.4.5. By End User
    • 6.2.6.5. Australia & New Zealand
    • 6.2.6.5.1. By Type
    • 6.2.6.5.2. By Process
    • 6.2.6.5.3. By Drug Type
    • 6.2.6.5.4. By Therapeutic Area
    • 6.2.6.5.5. By End User
    • 6.2.6.6. Indonesia
    • 6.2.6.6.1. By Type
    • 6.2.6.6.2. By Process
    • 6.2.6.6.3. By Drug Type
    • 6.2.6.6.4. By Therapeutic Area
    • 6.2.6.6.5. By End User
    • 6.2.6.7. Malaysia
    • 6.2.6.7.1. By Type
    • 6.2.6.7.2. By Process
    • 6.2.6.7.3. By Drug Type
    • 6.2.6.7.4. By Therapeutic Area
    • 6.2.6.7.5. By End User
    • 6.2.6.8. Singapore
    • 6.2.6.8.1. By Type
    • 6.2.6.8.2. By Process
    • 6.2.6.8.3. By Drug Type
    • 6.2.6.8.4. By Therapeutic Area
    • 6.2.6.8.5. By End User
    • 6.2.6.9. Vietnam
    • 6.2.6.9.1. By Type
    • 6.2.6.9.2. By Process
    • 6.2.6.9.3. By Drug Type
    • 6.2.6.9.4. By Therapeutic Area
    • 6.2.6.9.5. By End User
    • 6.2.6.10. Rest of APAC
    • 6.2.6.10.1. By Type
    • 6.2.6.10.2. By Process
    • 6.2.6.10.3. By Drug Type
    • 6.2.6.10.4. By Therapeutic Area
    • 6.2.6.10.5. By End User

7. Latin America Drug Discovery Services Market

• 7.1. Market Size & Forecast, 2019-2029
  • 7.1.1. By Value (USD Billion)
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Process
  • 7.2.3. By Drug Type
  • 7.2.4. By Therapeutic Area
  • 7.2.5. By End User
  • 7.2.6. By Country
    • 7.2.6.1. Brazil
    • 7.2.6.1.1. By Type
    • 7.2.6.1.2. By Process
    • 7.2.6.1.3. By Drug Type
    • 7.2.6.1.4. By Therapeutic Area
    • 7.2.6.1.5. By End User
    • 7.2.6.2. Mexico
    • 7.2.6.2.1. By Type
    • 7.2.6.2.2. By Process
    • 7.2.6.2.3. By Drug Type
    • 7.2.6.2.4. By Therapeutic Area
    • 7.2.6.2.5. By End User
    • 7.2.6.3. Argentina
    • 7.2.6.3.1. By Type
    • 7.2.6.3.2. By Process
    • 7.2.6.3.3. By Drug Type
    • 7.2.6.3.4. By Therapeutic Area
    • 7.2.6.3.5. By End User
    • 7.2.6.4. Peru
    • 7.2.6.4.1. By Type
    • 7.2.6.4.2. By Process
    • 7.2.6.4.3. By Drug Type
    • 7.2.6.4.4. By Therapeutic Area
    • 7.2.6.4.5. By End User
    • 7.2.6.5. Rest of Latin America
    • 7.2.6.5.1. By Type
    • 7.2.6.5.2. By Process
    • 7.2.6.5.3. By Drug Type
    • 7.2.6.5.4. By Therapeutic Area
    • 7.2.6.5.5. By End User

8. Middle East & Africa Drug Discovery Services Market

• 8.1. Market Size & Forecast, 2019-2029
  • 8.1.1. By Value (USD Billion)
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Process
  • 8.2.3. By Drug Type
  • 8.2.4. By Therapeutic Area
  • 8.2.5. By End User
  • 8.2.6. By Country
    • 8.2.6.1. Saudi Arabia
    • 8.2.6.1.1. By Type
    • 8.2.6.1.2. By Process
    • 8.2.6.1.3. By Drug Type
    • 8.2.6.1.4. By Therapeutic Area
    • 8.2.6.1.5. By End User
    • 8.2.6.2. UAE
    • 8.2.6.2.1. By Type
    • 8.2.6.2.2. By Process
    • 8.2.6.2.3. By Drug Type
    • 8.2.6.2.4. By Therapeutic Area
    • 8.2.6.2.5. By End User
    • 8.2.6.3. Qatar
    • 8.2.6.3.1. By Type
    • 8.2.6.3.2. By Process
    • 8.2.6.3.3. By Drug Type
    • 8.2.6.3.4. By Therapeutic Area
    • 8.2.6.3.5. By End User
    • 8.2.6.4. Kuwait
    • 8.2.6.4.1. By Type
    • 8.2.6.4.2. By Process
    • 8.2.6.4.3. By Drug Type
    • 8.2.6.4.4. By Therapeutic Area
    • 8.2.6.4.5. By End User
    • 8.2.6.5. South Africa
    • 8.2.6.5.1. By Type
    • 8.2.6.5.2. By Process
    • 8.2.6.5.3. By Drug Type
    • 8.2.6.5.4. By Therapeutic Area
    • 8.2.6.5.5. By End User
    • 8.2.6.6. Nigeria
    • 8.2.6.6.1. By Type
    • 8.2.6.6.2. By Process
    • 8.2.6.6.3. By Drug Type
    • 8.2.6.6.4. By Therapeutic Area
    • 8.2.6.6.5. By End User
    • 8.2.6.7. Algeria
    • 8.2.6.7.1. By Type
    • 8.2.6.7.2. By Process
    • 8.2.6.7.3. By Drug Type
    • 8.2.6.7.4. By Therapeutic Area
    • 8.2.6.7.5. By End User
    • 8.2.6.8. Rest of MEA
    • 8.2.6.8.1. By Type
    • 8.2.6.8.2. By Process
    • 8.2.6.8.3. By Drug Type
    • 8.2.6.8.4. By Therapeutic Area
    • 8.2.6.8.5. By End User

9. Competitive Landscape

• 9.1. List of Key Players and Their Offerings
• 9.2. Global Drug Discovery Services Company Market Share Analysis, 2022
• 9.3. Competitive Benchmarking, By Operating Parameters
• 9.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)

10. Impact of Covid-19 on Global Drug Discovery Services Market

11. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 11.1. General Electric
• 11.2. Eurofins Scientific
• 11.3. Syngene International Limited
• 11.4. Wuxi AppTec
• 11.5. Frontage Labs
• 11.6. Domainex
• 11.7. WIL Research Laboratories LLC
• 11.8. Shanghai Medicilon, Inc.
• 11.9. Labcorp Drug Development
• 11.10. Jubilant Biosys Ltd.
• 11.11. Evotec
• 11.12. Shanghai ChemPartner
• 11.13. Charles River Laboratories
• 11.14. Merck & Co. Inc.
• 11.15. Thermo Fisher Scientific Inc.
• 11.16. Other Prominent Players

12. Key Strategic Recommendations

13. Research Methodology

• 13.1. Qualitative Research
  • 13.1.1. Primary & Secondary Research
• 13.2. Quantitative Research
• 13.3. Market Breakdown & Data Triangulation
  • 13.3.1. Secondary Research
  • 13.3.2. Primary Research
• 13.4. Breakdown of Primary Research Respondents, By Region
• 13.5. Assumptions & Limitations